r It has been suggested that leucine is primarily responsible for the increase in muscle protein synthesis after protein ingestion because leucine uniquely activates the mTOR-p70S6K signalling cascade.
r We compared the effects of ingesting protein or an amount of leucine equal to that in the protein during a hyperinsulinaemic-euglycaemic clamp (to eliminate potential confounding as a result of differences in the insulinogenic effect of protein and leucine ingestion) on muscle anabolic signalling and protein turnover in 28 women.
r We found that protein, but not leucine, ingestion increased muscle p-mTOR Ser2448 and p-p70S6K Thr389 , although only protein, and not leucine, ingestion decreased muscle p-eIF2α
Ser51 and increased muscle protein synthesis.
Abstract It has been suggested that leucine is primarily responsible for the increase in muscle protein synthesis (MPS) after protein ingestion because leucine uniquely activates the mTOR-p70S6K signalling cascade. We tested this hypothesis by measuring muscle p-mTOR Ser2448 , p-p70S6K
Thr389 and p-eIF2α Ser51 , as well as protein turnover (by stable isotope labelled amino acid tracer infusion in conjunction with leg arteriovenous blood and muscle tissue sampling), in 28 women who consumed either 0.45 g protein kg −1 fat-free mass (containing 0.0513 g leucine kg
fat-free mass) or a control drink (n = 14) or 0.0513 g leucine kg −1 fat-free mass or a control drink (n = 14) during a hyperinsulinaemic-euglycaemic clamp procedure (HECP). Compared to basal conditions, the HECP alone (without protein or leucine ingestion) suppressed muscle protein breakdown by ß20% and increased p-mTOR Ser2448 and p-p70S6K Thr389 by >50% (all P < 0.05) but had no effect on p-eIF2α Ser51 and MPS. Both protein and leucine ingestion further
Introduction
Muscle mass is maintained by a tightly controlled balance between muscle protein synthesis (MPS) and muscle protein breakdown (MPB). During basal, postabsorptive conditions, the rate of MPB exceeds the rate of MPS, causing a net loss of protein (Rennie et al. 2004) . Meal intake compensates for the postabsorptive loss of muscle protein because dietary protein-derived amino acids stimulate MPS and insulin suppresses MPB (Rennie et al. 2004) . The postprandial net protein gain is largely determined by the amount of protein ingested because the postprandial increase in plasma amino acids stimulates MPS in a dose-dependent manner, whereas the plasma insulin concentration necessary to achieve maximal suppression of MPB (ß15-30 mU L −1 ) already occurs after consuming a small amount of protein or carbohydrate (Bohe et al. 2003; Greenhaff et al. 2008; Moore et al. 2009 ). The exact mechanism(s) responsible for the stimulatory effect of postprandial hyperaminoacidemia on MPS is unclear. Leucine probably plays a key role in stimulating postprandial MPS because it uniquely activates the mTOR-p70S6K signalling cascade (Atherton et al. 2010; Iwanaka et al. 2010; Moberg et al. 2014) , which is essential for myocellular hypertrophy (Goodman et al. 2011; Walker et al. 2011; Moro et al. 2016) . Furthermore, increasing the leucine content of mixed meals or protein beverages augments the postprandial increase in MPS (Rieu et al. 2006; Wall et al. 2013; Churchward-Venne et al. 2014; Murphy et al. 2016; Devries et al. 2018 ) and we have found that leucine, but not total protein, ingestion determines the increase in muscle mTOR-p70S6K (Smith et al. 2015c) . However, it is not known whether leucine alone is responsible for the increase in MPS after protein ingestion.
The present study aimed to compare the effects of ingesting protein or an amount of leucine equal to that in the protein on muscle protein turnover. Participants ingested either 0.45 g whey protein kg FFM, or 0.0513 g leucine kg −1 FFM alone during a hyperinsulinaemic-euglycaemic clamp procedure (HECP) to eliminate potential confounding as a result of differences in the insulinogenic effect of protein and leucine ingestion. 2 H-labelled phenylalanine and leucine tracers were infused throughout the study. Leg arteriovenous blood and thigh muscle biopsy sampling was used to determine net protein kinetics.
Methods

Human subjects research regulatory compliance
The study was approved and monitored by the Human Research Protection Office at Washington University School of Medicine (St Louis, MO, USA). Written informed consent was obtained from all participants before their participation.
Study participants
Twenty-eight sedentary (<1.5 h of exercise/week), 50-65-year-old postmenopausal women participated in the present study: 14 in the protein group and 14 in the leucine group. All potential participants completed a comprehensive medical examination, including a history and physical examination, a resting electrocardiogram, standard blood tests, and an oral glucose tolerance test. Exclusion criteria included evidence of chronic illness or significant organ dysfunction (e.g. diabetes, kidney disease), taking medications (including hormone replacement therapy) that could interfere with the action of insulin or protein metabolism, excessive alcohol intake (> 20 g per day), and smoking or chewing tobacco products. Participants' body fat mass and FFM were determined using dual energy X-ray absorptiometry (Lunar iDXA; GE Healthcare Lunar, Madison, WI, USA) and thigh muscle volume was determined using magnetic resonance imaging as described previously (Smith et al. 2015a) . Details concerning the age, body composition and thigh muscle volume of participants are presented in Table 1 . Thigh muscle volume (cm 3 ) 3,639 ± 87 3,568 ± 91 0.58
Data are the mean ± SEM; n = 14 per group.
Protein metabolism studies
Each participant completed two HECP in randomized order in conjunction with or without protein ingestion (n = 14) or in conjunction with or without leucine ingestion (n = 14). Before each HECP, participants were instructed to adhere to their usual diet and to refrain from vigorous physical activity for 3 days. for the subsequent 5 min). Euglycaemia (blood glucose ß5.6 mM) was maintained by variable rate infusion of 20% dextrose (Baxter, Deerfield, IL, USA). To adjust for the insulin-mediated suppression of whole body proteolysis, the phenylalanine and leucine tracer infusion rates were reduced to 0.08 μmol kg FFM −1 min −1 and 0.10 μmol kg FFM −1 min −1 , respectively, during the HECP. Participants in the protein group consumed either 0.45 g of whey protein (unflavored Unjury; ProSynthesis Laboratories, Inc., Reston, VA, USA) per kg FFM (containing 0.0513 g leucine per kg FFM) dissolved in 270 mL of water or an equivalent volume of water (control study) in small aliquots every 20 min during the 3 h HECP. The total amount of protein ingested was 20.7 ± 0.5 g (containing 2.4 ± 0.1 g leucine). To minimize changes in arterial plasma leucine and phenylalanine enrichments as a result of an increased amino acid appearance in plasma during protein ingestion, [5, 5, H 3 ]leucine and [ring-2 H 5 ]phenylalanine, equivalent to 5% and 6% of the leucine and phenylalanine content in whey protein, respectively, were added to the protein drinks. Participants in the leucine group consumed either 0.0513 g leucine (Sigma-Aldrich, Inc., St Louis, MO, USA) per kg FFM (total: 2.4 ± 0.1 g) enriched to 5% with [5,5,5-2 H 3 ]leucine or an equivalent volume of the control solution only in small aliquots every 20 min during the 3 h HECP. The protein or leucine ingestion and respective control studies were conducted in randomized order, 1-4 weeks apart.
Arterial and femoral venous blood samples were obtained immediately before starting the tracer infusions, every 6-7 min during the last 20 min of the basal period, 1 h and 2 h after starting the HECP, and every 6-7 min during last 20 min of the HECP. Additional arterial blood samples were obtained every 10 min during the HECP to monitor blood glucose concentration. Leg blood flow in the common femoral artery was measured at regular intervals between 2 h and 3 h after starting the tracer infusions (basal period) and between 1 h and 3 h after starting the HECP using Doppler ultrasound (M-Turbo; Sonosite Inc., Bothell, WA, USA) and a linear array 13 to 6 MHz frequency probe (Sonosite Inc.) (Radegran & Saltin, 1999) . In nine of the 14 subjects in each group, muscle tissue samples from the quadriceps femoris were obtained under local anaesthesia (lidocaine HCl, 2%; Hospira Inc., Lake Forest, IL, USA) using a Tilley-Henkel forceps 1 h and 4 h after starting the tracer infusions (basal period) and 3 h after starting the HECP to determine muscle protein fractional turnover and the contents of the key cell growth stimulators p-mTOR Ser2448 and p-p70S6K Thr389 , which sense an increase in amino acids, the eIF2 kinase p-GCN2 Thr899 , which senses uncharged t-RNA, and the inhibitory translation initiation factor p-eIF2α Ser51 .
Sample processing and analysis
Blood samples were collected in chilled tubes containing heparin (to determine glucose and insulin concentrations) or EDTA (to determine amino acid concentrations and enrichments). Samples were placed in ice and plasma was separated by centrifugation within 30 min of collection and then stored at −80°C until final analyses. Muscle samples were rinsed in ice-cold saline immediately after collection, cleared of visible fat and connective tissue, frozen in liquid nitrogen and stored at −80°C until final analysis.
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Plasma glucose concentration was determined using an automated glucose analyser (Yellow Spring Instruments Co, Yellow Springs, OH, USA). The plasma insulin concentrations were measured using a commercially available enzyme-linked immunosorbent assay (EMD Millipore, St Charles, MO, USA). Plasma phenylalanine and leucine concentrations and enrichments were determined using gas-chromatography/ mass-spectrometry (GC-MS; MSD 5973 System, Hewlett-Packard, Palo Alto, CA, USA) after adding known amounts of internal standards to each sample and converting the amino acids to their t-butyldimethylsilyl (t-BDMS) derivatives (Smith et al. 2007) . The concentrations of additional amino acids were determined by GC-MS using the EZ:faast Amino Acid Analysis kit (Phenomenex, Torrance, CA, USA).
To determine phenylalanine enrichment in muscle proteins and muscle free phenylalanine and leucine concentrations and enrichments, ß20 mg of each muscle biopsy sample was homogenized in 1 mL of trichloroacetic acid solution (3% w/v) after the addition of known amounts of internal standards. Muscle proteins were then precipitated by centrifugation and the supernatant, containing free amino acids, was collected. The pellet containing muscle proteins was hydrolysed in HCl. The supernatant, containing free amino acids was purified by passing it through a 0.2 μm filter. Amino acids in the hydrolysate and eluent were converted to their t-BDMS derivative and analysed by GC-MS (Smith et al. 2007) .
The concentrations of phosphorylated intramuscular amino acid sensing proteins and proteins involved in translation initiation (p-mTOR Ser2448 , p-p70S6K Thr389 , p-GCN2 Thr899 and p-eIF2α Ser51 ) were quantified by western analysis as described previously (Smith et al. 2015c) . Frozen muscle tissue was rapidly homogenized in ice-cold cell lysis buffer (Cell Signaling Technology, Beverly, MA, USA) and proteins were extracted (Yoshino et al. 2012) . Then, 20 μg of protein from each sample was loaded onto gradient (4-20%) polyacrylamide gels (Bio-Rad Laboratories, Hercules, CA, USA), separated by SDS-PAGE and transferred to Immobilo polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). The blotted membranes were incubated with the following primary antibodies: rabbit polyclonal anti-phospho-mTOR (Ser2448) (#2971; Cell Signaling Technology), rabbit monoclonal anti-phospho-p70S6K (Thr389) (#9234; Cell Signaling Technology), rabbit monoclonal anti-phospho-GCN2 (Thr899) (#75836; Abcam, Cambridge, UK) and rabbit monoclonal anti-phospho-eIF2α (Ser51) (#3398 Cell Signaling Technology). All blots were incubated with horseradish peroxidase-conjugated anti-rabbit antibodies and developed using Amersham ECL Select Western Blotting Detection Reagent (#RPN2235; GE Healthcare Life Sciences, Piscataway, NJ, USA). The p-mTOR Ser2448 and p-p70S6K
Thr389 data have been reported previously in a study evaluating the effects of protein and leucine ingestion on muscle p-mTOR Ser2448 and the action of insulin (Smith et al. 2015c) .
Calculations
Phenylalanine and leucine kinetics across the leg were calculated using a two-pool model and recently described equations (Smith et al. 2015b) :
Leg rate of disappearance (leg Rd)
Leg rate of appearance (leg, Ra) = Leg Rd − NB (3) where CT A and CT V are total (i.e. tracee + tracer) plasma amino acid concentrations in the artery and femoral vein, respectively; MPE A and MPE V represent the mole percent excess of the amino acids in arterial and femoral venous plasma, respectively; and PF is plasma flow (mL min −1 ) calculated from the measured blood flow adjusted for haematocrit (Hct). Leg Ra represents the rate of amino acid release into the vein from protein breakdown and leg Rd reflects the rate of arterial plasma amino acids taken up by the muscle for protein synthesis (phenylalanine) or protein synthesis and oxidation (leucine).
Phenylalanine intramuscular Ra from proteolysis and intramuscular Rd to protein synthesis were calculated using a three-pool model:
where MPE M is the mole percent excess of phenylalanine in the muscle free pool, and F M,A is inward transport,
The mixed muscle protein fractional synthesis rate (FSR) was calculated by dividing the increment in 
Statistical analysis
Statistical analyses were carried out using SPSS, version 24 (IBM Corp., Armonk, NY, USA). Student's t test was used to compare the basic characteristics of participants in the protein and leucine groups. Three-way ANOVA, with group (protein vs. leucine) as the between subject factor and study (control vs. protein or leucine ingestion) and time (basal vs. clamp) as within subject factors, was used to evaluate the effect of the HECP with and without concomitant protein or leucine ingestion on plasma metabolite and hormone concentrations, leg plasma flow, muscle free amino acid concentrations, intramuscular signalling protein contents and muscle protein turnover. When statistically significant interactions were found, Tukey's post hoc procedure was used to locate the differences. P < 0.05 was considered statistically significant. Data are presented as the mean ± SEM unless otherwise noted.
Results
Arterial plasma glucose and insulin concentrations and leg plasma flow (Table 2) During basal conditions, plasma glucose and insulin concentrations and leg plasma flow were not different among the protein and leucine groups and their respective control studies. During the HECP, the plasma glucose concentration was maintained at the 5.6 mM target in all studies; the insulin concentration increased ß10-fold and leg plasma flow increased by ß20% above basal values in all studies (no difference among groups and studies).
Arterial and venous plasma and muscle free amino acid concentrations ( Fig. 1 and Table 3) During basal conditions, plasma amino acid concentrations were not different among the protein and leucine groups and their respective control studies.
Arterial plasma total essential and non-essential amino acid concentrations decreased by ß15-30% during the HECP in the control studies and during the HECP with concomitant leucine ingestion but increased by ß65% (essential) and ß10% (non-essential) above basal values during the HECP with concomitant protein ingestion. Arterial and venous plasma phenylalanine concentrations decreased by ß25% during the HECP in the control studies and during the HECP with concomitant leucine ingestion, although they were not different or slightly greater than basal values during the HECP with concomitant protein ingestion; muscle phenylalanine concentration decreased by ß10-30% in all studies. Arterial and venous plasma leucine concentrations decreased by ß50% during the HECP in the control studies but increased by ß50% (venous) to 100% (arterial) during both protein and leucine ingestion. Muscle leucine concentration decreased by ß40% during the HECP in the control studies, did not change during the HECP with concomitant protein ingestion, and increased by ß50% with concomitant leucine ingestion.
Amino acid sensing and anabolic signalling in muscle (Fig. 2) Compared to basal conditions, the HECP alone increased both p-mTOR Ser2448 and p-p70S6K Thr38 but had no effect on p-GCN2 Thr899 and p-eIF2α Ser51 . Both protein and leucine ingestion augmented the HECP-induced increase in p-mTOR Ser2448 and p-p70S6K Thr38 , without a difference between groups. Protein, but not leucine, ingestion decreased p-eIF2α
Ser51 . Neither protein, nor leucine ingestion altered p-GCN2 Thr899 .
Leg phenylalanine and leucine kinetics (Fig. 3) During basal conditions, leg phenylalanine and leucine kinetics were not different among the protein and leucine groups and their respective control studies. Leg during the HECP alone or with leucine ingestion; total mean ± SEM). Leg phenylalanine release, an index of MPB, decreased by ß20% during the HECP alone and with concomitant protein and leucine ingestion. Intramuscular phenylalanine Ra, a measure of MPB, tended (P = 0.09) to decrease during the HECP in all studies (from 3506 ± 299 nmol min −1 during basal conditions to 3235 ± 255 nmol min −1 during the HECP; toal mean ± SEM of all studies), although the difference did not reach statistical significance, probably because of a lack of statistical power. Leg net phenylalanine balance changed from negative (net protein loss) during basal conditions to equilibrium during the HECP alone and the HECP with concomitant leucine ingestion, and to positive (net gain) during the HECP with concomitant protein ingestion. Leg leucine uptake was not affected by the HECP alone, whereas both protein and leucine ingestion markedly increased leg leucine uptake. Leg leucine release decreased by ß20-30% during the HECP alone and during the HECP with concomitant protein or leucine ingestion; accordingly, leucine net balance across the leg markedly increased during both protein and leucine ingestion.
Muscle protein FSR (Fig. 4) Compared to basal conditions, the muscle protein FSR was not affected by the HECP alone or the HECP with concomitant leucine ingestion but increased by ß100% with protein ingestion.
Discussion
The muscle anabolic effect of protein ingestion is proposed to be mediated by leucine because of its unique ability to activate mTOR-p70S6K, which is essential for regulating MPS (Atherton et al. 2010; Iwanaka et al. 2010; Goodman et al. 2011; Walker et al. 2011; Moberg et al. 2014; Moro et al. 2016) . We compared the effects of ingesting protein or an amount of leucine equal to that in the ingested protein on anabolic signalling and protein turnover in muscle during controlled physiological hyperinsulinaemia, as achieved using the HECP, to eliminate potential confounding as a result of differences in the insulinogenic effect of protein and leucine ingestion. Our data demonstrate that, compared to basal conditions, the HECP alone increased both p-mTOR Ser2448 and p-p70S6K
Thr38 but had no effect on p-eIF2α Ser51 or the rate of MPS, and also decreased the rate of MPB. Both protein and leucine ingestion during the HECP caused a similar further increase in p-mTOR Ser2448 and p-p70S6K Thr389 ; however, only protein, but not leucine, ingestion decreased p-eIF2α Ser51 (which permits translation initiation) and increased the rate of MPS. The protein ingestion-induced decrease in p-eIF2α Artery Basal 66 ± 2 6 7 ± 2 6 8 ± 2 6 8 ± 2 HECP 54 ± 2 * 75 ± 2 * , †, ‡ 57 ± 2 * 50 ± 2 * Vein Basal 71 ± 3 7 1 ± 2 7 3 ± 3 7 2 ± 2 HECP 52 ± 3 * 66 ± 2 †, ‡ 56 ± 3 * 47 ± 2 * , † Muscle Basal 85 ± 4 9 1 ± 3 7 7 ± 6 8 1 ± 6 HECP 67 ± 5 § 84 ± 12 § 63 ± 7 § 56 ± 5 § Leucine (μM) Artery Basal 122 ± 5 129 ± 3 125 ± 5 123 ± 6 HECP 62 ± 4 * 230 ± 14 * , † 67 ± 4 * 255 ± 18 * , † Vein Basal 127 ± 5 132 ± 4 127 ± 6 127 ± 6 HECP 58 ± 4 * 176 ± 10 * , † 63 ± 5 * 194 ± 16 * , † Muscle Basal 150 ± 8 172 ± 9 151 ± 7 150 ± 7 HECP 88 ± 9 * 184 ± 18 †, ‡ 92 ± 10 * 233 ± 15 * , † Data are the mean ± SEM during the last 20 min of the basal period and the HECP. Three-way ANOVA revealed: (i) a significant group (whey vs. leucine) × study (control vs. protein or leucine ingestion) × time (basal vs. clamp) interaction for arterial and venous plasma phenylalanine concentrations, muscle free leucine concentrations, and total essential and non-essential amino acid concentrations; (ii) a significant study (control vs. protein or leucine ingestion) × time (basal vs. clamp) interaction for arterial and venous plasma leucine concentrations; and (iii) a significant main effect of time for muscle free phenylalanine concentrations. * Significantly different from corresponding basal value (P < 0.05). † Significantly different from corresponding control value (P < 0.05). ‡ Significantly different from corresponding value in the leucine group (P < 0.05). § Significant main effect of the HECP (P < 0.001).
MPS was observed independently of the method used to measure muscle protein turnover (i.e. the arteriovenous phenylalanine tracer balance technique in conjunction with either a two-or three-pool modelling approach or by directly measuring the phenylalanine tracer incorporation rate into muscle protein). Neither protein, nor leucine ingestion augmented the insulin-mediated suppression of MPB or leg phenylalanine and leucine rates of release. These results confirm the potent anti-proteolytic effect of insulin and muscle anabolic effect of protein ingestion, as well as the dissociation among key anabolic signalling events in muscle and MPS; they also provide novel insights into the regulation of muscle protein turnover by nutrient ingestion.
The results of the present study are consistent with those obtained in a recent study conducted in very old mice (aged 25 months) reporting that oral gavage with a leucine-enriched protein solution, but not a matched amount of leucine alone, stimulated MPS (Dijk et al. 2018) . However, our results are inconsistent with the observation that an I.V. or orally administered 'flooding' dose of leucine acutely increased the rate of MPS in healthy young men (Smith et al. 1992; Wilkinson et al. 2013 ). The differences in the results among studies could be a result of age-associated anabolic resistance (Cuthbertson et al. 2005; Smith et al. 2012) . However, we consider this doubtful because, unlike leucine, protein ingestion did increase the rate of MPS both in our middle-aged J Physiol 596.19 women and the aged rats studied by Dijk et al. (2018) . Therefore, the differences in results among studies are probably related to the dose and mode of delivery, comprising a ß3.5 g 'flooding' bolus (Smith et al. 1992; Wilkinson et al. 2013) vs. slow sustained (180 min) delivery of ß2.4 g leucine in our protein and leucine groups, and/or the controlled hyperinsulinaemia and ensuing hypoaminoacidema during the HECP in our study. Hypoaminoacidemia itself inhibits MPS (Kobayashi et al. 2003) and the results from our study suggest that leucine alone is insufficient to overcome this blockade because the availability of other (essential) amino acids needed for protein synthesis is rate limiting (Wolfe, 2017) . This notion is supported by the results from studies conducted in neonatal pigs and adult rats that found I.V. leucine administration transiently increased the rate of MPS and this increase was only sustained when additional amino acids were provided (Anthony et al. 2002; Escobar et al. 2005; Wilson et al. 2010) . Indeed, it has been found that leucine infusion causes a decrease in intramyocellular total amino acid concentration (Alvestrand et al. 1990) , probably because it promotes amino acid incorporation into protein until their availability becomes rate-limiting (Wolfe, 2017) . Moreover, there is no dose-response relationship between the amount of leucine given and the initial rate of MPS (Crozier et al. 2005) . By contrast, protein and essential amino acid ingestion and I.V. mixed amino acid infusion elicit a dose-dependent increase in MPS (Bohe et al. 2003; Cuthbertson et al. 2005; Moore et al. 2009 ) and increasing the leucine content of mixed meals Figure 3 . Leg phenylalanine and leucine kinetics Leg phenylalanine and leucine kinetics assessed using the two-pool arterio-venous balance model during basal conditions (white bars) and during the hyperinsulinaemic euglycaemic clamp procedure (black bars). Data are the mean ± SEM. Three-way ANOVA revealed: (i) a significant group (whey vs. leucine) × study (control vs. protein or leucine ingestion) × time (basal vs. clamp) interaction for leg phenylalanine uptake and net balance; (ii) a significant study (control vs. protein or leucine ingestion) × time (basal vs. clamp) interaction for leg leucine uptake and net balance; and (iii) a significant main effect of time for leg phenylalanine and leucine release. * Significantly different from corresponding basal value (P < 0.05). † Significantly different from corresponding control value (P < 0.05). ǂ Significantly different from corresponding value in the leucine group (P < 0.05). § Significant main effect of the hyperinsulinaemic-euglycaemic clamp (P < 0.001). or protein beverages dose-dependently augments the postprandial increase in MPS (Katsanos et al. 2006; Rieu et al. 2006; Wall et al. 2013; Churchward-Venne et al. 2014; Murphy et al. 2016; Devries et al. 2018) . Taken together, these data suggest that leucine contributes to but does not cause the muscle anabolic effect of protein ingestion, which requires the presence of additional amino acids. The canonical mTOR-p70S6K signalling pathway is considered to be the key regulator of MPS (Goodman et al. 2011; Walker et al. 2011; Moro et al. 2016) . However, the results from our study suggest that mTOR independent signalling pathways are responsible for translation initiation because the HECP alone and the HECP with both concomitant protein and leucine ingestion increased mTOR Ser2448 and p-p70S6K Thr389 , although only protein ingestion decreased p-eIF2α Ser51 , which permits translation initiation. The upstream mediators responsible for the differences in eIF2α
Ser51 phosphorylation during the HECP with and without protein and leucine ingestion are not known. The results from our study suggest that the intracellular amino acid sensor GCN2, which can regulate eIF2α activity (Kimball, 2002; Gordon et al. 2013; Moro et al. 2016) , is not involved because GCN2 phosphorylation was not different during protein and leucine ingestion. Indeed, GCN2 phosphorylation was not altered by either the HECP or protein and leucine J Physiol 596.19 ingestion, despite marked differences in intramyocellular amino acid concentrations during basal conditions and the HECP with and without protein and leucine ingestion. The most probable explanation for this observation is that intramyocellular amino acid concentrations did not fall below a critical threshold of amino acid 'deprivation' that activates GCN2 (Kimball, 2002; Gordon et al. 2013) .
The increased leucine uptake by muscle during leucine ingestion was presumably oxidized because leucine ingestion did not increase MPS and the intramyocellular leucine concentration during leucine ingestion was not much greater than that during protein ingestion despite similar leg leucine uptake rates. This finding is consistent with studies that evaluated the fate of leucine during I.V. leucine infusion more directly by measuring the production of α-ketoisocaproic acid, a leucine oxidation product (Abumrad et al. 1982; Alvestrand et al. 1990; Nair et al. 1992) .
Neither protein nor leucine ingestion augmented the insulin-mediated suppression of MPB, assessed as the intracellular appearance of phenylalanine from proteolysis (three-pool model) or leg phenylalanine release (two-pool model). This finding is consistent with the results from previous studies that found the ingestion or infusion of complete or essential amino acid mixtures did not alter MPB (Biolo et al. 1997; Glynn et al. 2010a; Glynn et al. 2013) . By contrast, I.V. infusions of a mixture of branched chain amino acids or leucine alone (Louard et al. 1990; Nair et al. 1992; Louard et al. 1995) or ingestion of a leucine-enriched essential amino acid solution (Glynn et al. 2010b ) inhibited MPB. The reasons for the differences in results among those studies are not clear, although they could be a result of differences in the dose of amino acids/protein administered and/or the prevailing insulin concentration. In the present study, MPB was probably already maximally suppressed by insulin during the HECP alone because plasma insulin increased from ß5-6 mU L −1 during basal conditions to ß50-60 mU L −1 during the HECP and MPB is maximally suppressed at plasma insulin concentrations > 30 mU L −1 (Greenhaff et al. 2008 ).
Summary and conclusion
The results from the present study confirm the potent anti-proteolytic effect of insulin and the muscle anabolic effect of protein ingestion and provide new insights into the regulation of MPS by demonstrating that leucine and mTOR signalling alone are not responsible for the muscle anabolic effect of protein ingestion during physiological hyperinsulinaemia, probably because they fail to signal to eIF2α to initiate translation and/or because additional amino acids are needed to sustain translation.
